drugset / Trial / NCT00690846
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.
Timeline
- Start
- 2007-07
- Primary completion
- 2007-07
- Completion
- 2007-07
Outcome
Outcome not reported
Stopped: “Dr. Jorizzo has withdrawn from this study due to time it is taking to start”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |